---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001983"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:18:23.899399+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Chromocell renamed Channel Therapeutics, reincorporates in Nevada; pipeline milestones expected soon

## Summary
- Name change to Channel Therapeutics effective Nov 18, 2024; reincorporation in Nevada for lower taxes and strategic flexibility.
- Depot program for postoperative nerve blocks: sustained drug release over 96 hours in animals; efficacy results imminent.
- Eye pain program: drops well tolerated in animals; efficacy results in weeks, toxicology data late Q1 2025, Phase II in Q2 2025.
- Chronic pain program exploring program-specific financing; kickoff expected in Q1 2025.

## SEC filing metadata
- accession: 0001753926-24-001983
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001983/0001753926-24-001983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001983/g084575_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001983
- JSON: https://secwatch.observer/filing/0001753926-24-001983.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.